Please note: AABB reserves the right to make updates to this program.
Live Program Date: Wednesday, April 25, 2018 -
Master Program Number: 18EL-330 (see program format numbers below under Registration)
Educational Track: Scientific
Topic: Cellular Therapies
Intended Audience: Hospital Staff, Laboratory Staff, Physicians, Research Scientist, Resident/Fellow, Scientists, Student (MD, MT, SBB), Technologist
Teaching Level: Basic to Intermediate
Directors: Lisa M. Shave MS, MLS(ASCP)CMSBBCM, Medical Laboratory Technology Program Coordinator & Professor, Mercer County Community College, West Windsor, NJ, Medical Laboratory Scientist, Pennsylvania Hospital, Philadelphia, PA; Hatem Sabaawy, MD, PhD, Assistant Professor of Medicine, Director of Cell and Gene Therapy, Rutgers University, New Brunswick, NJ
Moderator: Lisa M. Shave MS, MLS(ASCP)CMSBBCM, Medical Laboratory Technology Program Coordinator & Professor, Mercer County Community College, West Windsor, NJ, Medical Laboratory Scientist, Pennsylvania Hospital, Philadelphia, PA
Speaker: Hatem Sabaawy, MD, PhD, Assistant Professor of Medicine, Director of Cell and Gene Therapy, Rutgers University, New Brunswick, NJ
After participating in this educational activity, participants should be able to:
- List different cell products that could be used for therapy.
- Explain the process of using high-quality manufacturing for different cell types originating from blood and bone marrow.
- Identify methods for cell product quality control.
- Examine the promise of cell and regenerative therapy.
- Recognize the basics of cell immunotherapy.
The program will focus on novel approaches for cell therapy using blood and bone marrow cell components for treatment and will provide a description of quality control methods for generation of cell therapy products and some case studies from clinical trials.
| || ||
|Single Viewer: On-Demand||
|Group Viewing: On-Demand||
Hatem E. Sabaawy, MD, PhD is an assistant professor of medicine at Rutgers Robert Wood Johnson Medical School, an assistant professor of cellular and molecular pharmacology at the Rutgers Graduate School of Biomedical Sciences, director of the Cell and Gene Therapy Good Manufacturing Practice Facility at RWJMS, a member of the executive committee of the Stem Cell Institute of New Jersey, and a principal investigator at Rutgers Cancer Institute of New Jersey Molecular and Regenerative Medicine program.
Dr. Sabaawy had his medical residency and graduate training at Cairo University Hospitals in Cairo, Egypt, and New York Medical College in Valhalla, NY in clinical Hematology with PhD in Genetic Pharmacology from the Gene Therapy program at New York Medical College. He went on to complete a fellowship at the Transplantation and Immunology Branch of the Center for Cancer Research at the National Institutes of Health (NIH) and the National Cancer Institute (NCI) in Bethesda, MD. Currently, his work at Rutgers Cancer Institute of New Jersey is focused on stem cells, regenerative medicine, drug discovery and immunotherapy.